Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5505-5512

  Gucalp, Ayca ^a,c   Tolaney, Sara ^d   Isakoff, Steven J ^e   Ingle, James N ^f   Liu, Minetta C ^g   Carey, Lisa A ^h   Blackwell, Kimberly ⁱ   Rugo, Hope ^j   Nabell, Lisle ^k   Forero, Andres ^k   Stearns, Vered ^l   Doane, Ashley S ^a   Danso, Michael ^a   Moynahan, Mary Ellen ^a   Momen, Lamia F ^a   Gonzalez, Joseph M ^a   Akhtar, Arooj ^a   Giri, Dilip D ^b   Patil, Sujata ^b   Feigin, Kimberly N ^a   Hudis, Clifford A ^a,c   Traina, Tiffany A ^a,c   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Department of Pathology ^*  (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f MAYO CLINIC   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTHRACYCLINE DERIVATIVE; BICALUTAMIDE; CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; PROGESTERONE RECEPTOR; SEX HORMONE BINDING GLOBULIN; TAXANE DERIVATIVE; TESTOSTERONE; TRASTUZUMAB;

ADULT; AGED; ANOREXIA; ARTICLE; BACKACHE; BASAL LIKE BREAST CANCER; BREAST CANCER; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPERBILIRUBINEMIA; LIMB PAIN; MAJOR CLINICAL STUDY; MASTALGIA; MASTECTOMY; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; VAGINAL DRYNESS;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HORMONES; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NITRILES; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 84886425456     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-3327     Document Type: Article

References (35)

1. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007;109: 1721-8.
2. Kassam F, Enright K, Dent R, Dranitsaris G, Myers J, Flynn C, et al. Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 2009;9:29-33.
3. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007;13:4429-34.
4. Doane AS, Danso M, Lal P, Donaton M, Zhang L, Hudis C, et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006;25:3994-4008.
5. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P, Larsimont D, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71.
6. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
7. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression metaanalysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Med Genomics 2009;2:59.
8. Levine D, Park K, Juretzka M, Esch J, Hensley M, Aghajanian C, et al. A phase II evaluation of goserelin and bicalutamide in patients with ovarian cancer in second or higher complete clinical disease remission. Cancer 2007;110:2448-56.
9. De Leo V, Lanzetta D, D'Antona D, la Marca A, Morgante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:99-102.
10. Muderris II, BayramF, Ozcelik B, Guven M. New alternative treatment in hirsutism: bicalutamide 25 mg/day. Gynecol Endocrinol 2002;16:63-6.
11. Bahceci M, Tuzcu A, Canoruc N, Tuzun Y, Kidir V, Aslan C. Serum Creactive protein (CRP) levels and insulin resistance in non-obese women with polycystic ovarian syndrome, and effect of bicalutamide on hirsutism, CRP levels and insulin resistance. Horm Res 2004;62: 283-7.
12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10: 5367-74.
13. Perrault DJ, Logan DM, Stewart DJ, Bramwell VH, Paterson AH, Eisenhauer EA. Phase II study of flutamide in patients with metastatic breast cancer. A National Cancer Institute of Canada Clinical Trials Group study. Invest New Drugs 1988;6:207-10.
14. Zhao TP, He GF. A phase II clinical trial of flutamide in the treatment of advanced breast cancer. Tumori 1988;74:53-6.
15. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study. Mod Pathol 2011; 24:924-31.
16. Gonzalez-Angulo AM, Stemke-Hale K, Palla SL, Carey M, Agarwal R, Meric-Berstam F, et al. Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer. Clin Cancer Res 2009;15:2472-8.
17. Loibl S, Muller BM, von Minckwitz G, Schwabe M, Roller M, Darb-Esfahani S, et al. Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;130: 477-87.
18. Gucalp A, Gupta G, Patil S, Wen Y, Akram M, Brogi E, et al. P4-02-04: androgen receptor (AR) expression in a cohort of patients (pts) with triple negative breast cancer (TNBC). Cancer Res 2012;71: P4-02-4.
19. Lin NU, Claus E, Sohl J, Razzak AR, Arnaout A, Winer EP. Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 2008;113:2638-45.
20. Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong Y, et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). ASCO Meeting Abstracts 2009;27:543.
21. Dent R, HannaWM,Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat 2009;115:423-8.
22. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28:2784-95.
23. Cochrane D, Bernales S, Jacobsen B, D'Amato N, Guerrero J, Gomez F, et al. Preclinical evaluation of enzalutamide in breast cancer models. Cancer Res 2012;72:P2-14-02.
24. Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, et al. Expression of androgen receptors in primary breast cancer. Ann Oncol 2010;21: 488-92.
25. Park S, Koo JS, Kim MS, Park HS, Lee JS, Kim SI, et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 2011;22: 1755-62.
26. Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, et al. Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 2011;22:1288-94.
27. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 2011;20:119-31.
28. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 2008;10:542-8.
29. Baselga J, Gomez P, Awada A, Greil R, Braga S, Climent MA, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression-free survival (PFS) in metastatic triple-negative breast cancer (TNBC): results of a randomized phase II study (BALI-1). Ann Oncol 2010;21:viii96-viii121.
30. Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol 2012;30:2615-23.
31. O'Shaughnessy J, Osborne C, Pippen JE, Yoffe M, Patt D, Rocha C, et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 2011;364:205-14.
32. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
33. Gucalp A, Tolaney S, Isakoff S, Ingle J, Liu M, Carey L, et al. Endocrine biomarkers in response to AR-inhibition with bicalutamide for the treatment of AR(+), ER/PR(-) metastatic breast cancer (MBC) (TBCRC011). Cancer Res 2012;72:P6-05-2.
34. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptornegative breast cancer. Breast Cancer Res 2011;13:R36.
35. Naderi A, Liu J. Inhibition of androgen receptor and Cdc25A phosphatase as a combination targeted therapy in molecular apocrine breast cancer. Cancer Lett 2010;298:74-87.